202 related articles for article (PubMed ID: 8035394)
1. A double blind study comparing the efficacy and safety of enteric coated naproxen to naproxen in the management of NSAID intolerant patients with rheumatoid arthritis and osteoarthritis. Naproxen EC Study Group.
Caldwell JR; Roth SH
J Rheumatol; 1994 Apr; 21(4):689-95. PubMed ID: 8035394
[TBL] [Abstract][Full Text] [Related]
2. Enteric coated naproxen; a double blind trial comparing the tolerance of enteric coated and standard formulations.
Huskisson EC; Bernstein RM; Coppock JS; Davies PG; Doyle DV; Platt PR; Scott DL; Witherington RH; Wojtulewski JA
Eur J Rheumatol Inflamm; 1992; 12(2):27-30. PubMed ID: 1364935
[TBL] [Abstract][Full Text] [Related]
3. Impact of concomitant low-dose aspirin on the safety and tolerability of naproxen and esomeprazole magnesium delayed-release tablets in patients requiring chronic nonsteroidal anti-inflammatory drug therapy: an analysis from 5 Phase III studies.
Angiolillo DJ; Datto C; Raines S; Yeomans ND
J Thromb Thrombolysis; 2014 Jul; 38(1):11-23. PubMed ID: 24368727
[TBL] [Abstract][Full Text] [Related]
4. Diclofenac/misoprostol: the European clinical experience.
McKenna F
J Rheumatol Suppl; 1998 May; 51():21-30. PubMed ID: 9596551
[TBL] [Abstract][Full Text] [Related]
5. Enteric-coated and plain naproxen tablets in osteoarthritis; tolerability and efficacy.
Lehn OF; Jensen ON; Andersen LA; Christensen KA; Solheim L; Barslev J; Mjølstad W; Wiig G; Ibfelt HH; Kjønniksen T
Eur J Rheumatol Inflamm; 1992; 12(2):31-6. PubMed ID: 1364936
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of valdecoxib in treating the signs and symptoms of severe rheumatoid arthritis: a 12-week, multicenter, randomized, double-blind, placebo-controlled study.
Gibofsky A; Rodrigues J; Fiechtner J; Berger M; Pan S
Clin Ther; 2007 Jun; 29(6):1071-85. PubMed ID: 17692722
[TBL] [Abstract][Full Text] [Related]
7. Multicenter, randomized, double-blind, active-controlled, parallel-group trial of the long-term (6-12 months) safety of acetaminophen in adult patients with osteoarthritis.
Temple AR; Benson GD; Zinsenheim JR; Schweinle JE
Clin Ther; 2006 Feb; 28(2):222-35. PubMed ID: 16678643
[TBL] [Abstract][Full Text] [Related]
8. Valdecoxib is associated with improved dyspepsia-related health compared with nonspecific NSAIDs in patients with osteoarthritis or rheumatoid arthritis.
Rabeneck L; Goldstein JL; Vu A; Mayne TJ; Rublee DA
Am J Gastroenterol; 2005 May; 100(5):1043-50. PubMed ID: 15842577
[TBL] [Abstract][Full Text] [Related]
9. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo.
Bensen WG; Zhao SZ; Burke TA; Zabinski RA; Makuch RW; Maurath CJ; Agrawal NM; Geis GS
J Rheumatol; 2000 Aug; 27(8):1876-83. PubMed ID: 10955327
[TBL] [Abstract][Full Text] [Related]
10. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis.
Goldstein JL; Correa P; Zhao WW; Burr AM; Hubbard RC; Verburg KM; Geis GS
Am J Gastroenterol; 2001 Apr; 96(4):1019-27. PubMed ID: 11316141
[TBL] [Abstract][Full Text] [Related]
11. A comparison of Naprelan and Naprosyn in the treatment of osteoarthritis of the knee.
Schiff MH
Am J Orthop (Belle Mead NJ); 1996 Sep; 25(9 Suppl):14-20. PubMed ID: 8886213
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy and safety of Naprelan versus Naprosyn in the treatment of rheumatoid arthritis.
Lisse JR
Am J Orthop (Belle Mead NJ); 1996 Sep; 25(9 Suppl):21-9. PubMed ID: 8886214
[TBL] [Abstract][Full Text] [Related]
13. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
Hochberg MC
Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
[TBL] [Abstract][Full Text] [Related]
14. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study.
Singh G; Fort JG; Goldstein JL; Levy RA; Hanrahan PS; Bello AE; Andrade-Ortega L; Wallemark C; Agrawal NM; Eisen GM; Stenson WF; Triadafilopoulos G;
Am J Med; 2006 Mar; 119(3):255-66. PubMed ID: 16490472
[TBL] [Abstract][Full Text] [Related]
15. Prevention with sucralfate gel of NSAID-induced gastroduodenal damage in arthritic patients.
Miglioli M; Bianchi Porro G; Vaira D; Menegatti M; Brunetti G; Petrillo M; Ardizzone S; Frizziero L; Montrone F; Grandinetti G
Am J Gastroenterol; 1996 Nov; 91(11):2367-71. PubMed ID: 8931419
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and relative bioavailability of a fixed-dose combination of enteric-coated naproxen and non-enteric-coated esomeprazole magnesium.
Wang-Smith L; Fort J; Zhang Y; Sostek M
J Clin Pharmacol; 2012 May; 52(5):670-80. PubMed ID: 21628602
[TBL] [Abstract][Full Text] [Related]
17. The comparative risk and predictors of adverse gastrointestinal events in rheumatoid arthritis and osteoarthritis: a prospective 13 year study of 2131 patients.
Wolfe F; Hawley DJ
J Rheumatol; 2000 Jul; 27(7):1668-73. PubMed ID: 10914849
[TBL] [Abstract][Full Text] [Related]
18. Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis.
Kivitz A; Eisen G; Zhao WW; Bevirt T; Recker DP
J Fam Pract; 2002 Jun; 51(6):530-7. PubMed ID: 12100776
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of enteric-coated naproxen in the treatment of osteoarthritis and rheumatoid arthritis: a double-blind comparison with standard naproxen followed by an open-label trial.
Bellamy N; Beaulieu A; Bombardier C; Huang S; Kraag G; Ménard HA; Russell AS; Tannenbaum H; Willans M; Campbell J
Curr Med Res Opin; 1992; 12(10):640-51. PubMed ID: 1633722
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety of naproxen and esomeprazole magnesium fixed-dose combination: phase III study in patients at risk for NSAID-associated gastric ulcers.
Sostek MB; Fort JG; Estborn L; Vikman K
Curr Med Res Opin; 2011 Apr; 27(4):847-54. PubMed ID: 21319944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
